Faron Pharmaceuticals Oy
LSE:FARN
Balance Sheet
Balance Sheet Decomposition
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy
Balance Sheet
Faron Pharmaceuticals Oy
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
11
|
11
|
9
|
4
|
7
|
4
|
7
|
7
|
7
|
10
|
|
| Cash |
0
|
0
|
0
|
11
|
11
|
9
|
4
|
7
|
4
|
7
|
7
|
7
|
10
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
1
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
0
|
1
|
1
|
2
|
2
|
1
|
2
|
4
|
2
|
2
|
1
|
|
| Total Current Assets |
1
|
14
|
1
|
14
|
14
|
13
|
7
|
9
|
7
|
12
|
10
|
9
|
11
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
15
+664%
|
2
-85%
|
15
+583%
|
16
+6%
|
15
-5%
|
8
-46%
|
10
+28%
|
8
-18%
|
13
+58%
|
11
-14%
|
10
-9%
|
13
+23%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
2
|
3
|
4
|
3
|
2
|
2
|
6
|
9
|
5
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
2
|
2
|
2
|
3
|
2
|
2
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
4
|
|
| Other Current Liabilities |
0
|
0
|
2
|
0
|
3
|
5
|
0
|
1
|
2
|
1
|
0
|
1
|
0
|
|
| Total Current Liabilities |
1
|
2
|
2
|
2
|
5
|
8
|
6
|
6
|
7
|
7
|
10
|
15
|
10
|
|
| Long-Term Debt |
2
|
1
|
2
|
1
|
2
|
2
|
2
|
3
|
3
|
3
|
11
|
9
|
8
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
4
|
|
| Total Liabilities |
3
N/A
|
4
+32%
|
3
-8%
|
4
+9%
|
7
+102%
|
10
+38%
|
8
-25%
|
9
+13%
|
10
+19%
|
10
+0%
|
23
+122%
|
25
+12%
|
22
-12%
|
|
| Equity | ||||||||||||||
| Common Stock |
1
|
4
|
3
|
4
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Retained Earnings |
2
|
8
|
4
|
8
|
6
|
2
|
2
|
1
|
5
|
0
|
14
|
18
|
12
|
|
| Other Equity |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
11
N/A
|
1
N/A
|
11
N/A
|
8
-25%
|
5
-44%
|
0
-92%
|
2
+336%
|
2
N/A
|
3
N/A
|
11
N/A
|
15
-32%
|
10
+36%
|
|
| Total Liabilities & Equity |
2
N/A
|
15
+664%
|
2
-85%
|
15
+583%
|
16
+6%
|
15
-5%
|
8
-46%
|
10
+28%
|
8
-18%
|
13
+58%
|
11
-14%
|
10
-9%
|
13
+23%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
25
|
23
|
25
|
23
|
26
|
29
|
31
|
43
|
47
|
76
|
85
|
98
|
105
|
|